FLJ25371 Inhibitors
FLJ25371 inhibitors represent a class of chemical compounds designed to target and modulate the activity of the protein encoded by the FLJ25371 gene. This gene, also known by alternative designations, encodes a protein with roles in cellular processes such as signal transduction, protein-protein interactions, and regulation of specific molecular pathways. FLJ25371 inhibitors are typically small molecules that bind to this protein or interfere with its function at a biochemical level, disrupting its normal role within the cell. These inhibitors can be tailored to achieve a high degree of specificity, minimizing off-target interactions and maximizing the effective disruption of FLJ25371-associated pathways.
The design and optimization of FLJ25371 inhibitors require a deep understanding of the structural and functional characteristics of the FLJ25371 protein. Researchers often study the three-dimensional structure of the protein, identifying potential binding pockets or sites where inhibition can occur. High-throughput screening and structure-based drug design approaches may be employed to identify lead compounds. These inhibitors can be useful tools for probing the biological functions of FLJ25371 in experimental models, offering insight into the molecular pathways it influences. By utilizing FLJ25371 inhibitors, researchers can better understand the biological significance of this protein, its interactions with other molecules, and its role in complex cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a steroidal metabolite of fungi that acts as a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, wortmannin can lead to reduced phosphorylation and activation of AKT, which in turn could diminish the downstream signaling that may be necessary for the functional activity of FLJ25371. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a synthetic molecule that inhibits PI3K. Inhibition of the PI3K/AKT pathway by LY294002 would decrease the phosphorylation of downstream targets that could be involved in FLJ25371 activity, thereby leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a macrolide compound that inhibits mTOR (mechanistic target of rapamycin). By inhibiting mTOR, rapamycin can suppress the mTORC1 signaling pathway, which may indirectly decrease the activity of FLJ25371 by reducing the synthesis of proteins that FLJ25371 needs for its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a pyridinyl imidazole that acts as a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK can alter the stress response and inflammatory pathways that may indirectly affect the functional activity of FLJ25371 by altering the cellular context in which FLJ25371 operates. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a synthetic compound that inhibits MEK, which is upstream of ERK in the MAPK pathway. By inhibiting ERK phosphorylation and activation, PD98059 can lead to dampened signaling that may be required for FLJ25371 functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor of the c-Jun N-terminal kinase (JNK). Inhibition of JNK activity could impact transcription factors and genes that are necessary for the proper function of FLJ25371, thus indirectly leading to its inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, preventing the activation of MAPK/ERK. This disruption could potentially impede signaling events that are essential for the functional activity of FLJ25371. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with broad specificity. It may inhibit kinases that phosphorylate substrates necessary for FLJ25371 activity, thereby indirectly reducing its functional activity. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide is an inhibitor of dihydroorotate dehydrogenase involved in pyrimidine synthesis. By limiting pyrimidine synthesis, leflunomide could reduce the proliferation of cells that express FLJ25371, indirectly leading to decreased functional activity of FLJ25371. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, inducing cellular stress responses. These responses could indirectly inhibit FLJ25371 if it is involved in pathways sensitive to proteostatic stress. | ||||||